The purpose of this guideline is to provide information for the interpretation of clinical
dihydropyrimidine dehydrogenase (DPYD) genotype tests so that the results can be used to …

The fluoropyrimidines are the mainstay chemotherapeutic agents for the treatment of many
types of cancers. Detoxifying metabolism of fluoropyrimidines requires dihydropyrimidine …

In clinical practice, 25–30% of the patients treated with fluoropyrimidines experience severe
fluoropyrimidine‐related toxicity. Extensively clinically validated DPYD genotyping tests are …

The fluoropyrimidine anticancer drugs, especially 5-fluorouracil (5-FU) and capecitabine,
are frequently prescribed for several types of cancer, including breast, colorectal, head and …

Fluoropyrimidines (FPs), mainly 5-fluorouracil (5-FU) and its oral prodrug capecitabine
(Cap), remain the backbone of the treatment of many different solid tumors. Despite their …

Despite advances in the field of pharmacogenetics (PGx), clinical acceptance has remained
limited. The Dutch Pharmacogenetics Working Group (DPWG) aims to facilitate PGx …

Purpose Fluoropyrimidines are frequently prescribed anticancer drugs. A polymorphism in
the fluoropyrimidine metabolizing enzyme dihydropyrimidine dehydrogenase (DPD; ie …

Background The best-known cause of intolerance to fluoropyrimidines is dihydropyrimidine
dehydrogenase (DPD) deficiency, which can result from deleterious polymorphisms in the …

Background Fluoropyrimidine treatment can result in severe toxicity in up to 30% of patients
and is often the result of reduced activity of the key metabolic enzyme dihydropyrimidine …

A prominent example of the potential application of pharmacogenomics and
pharmacogenetics to oncology is the study of dihydropyrimidine dehydrogenase (DPD) in 5 …